Vildalgiptin as a dipeptidyl peptidase-4 inhibitor treatment in STZ-diabetic newborn rats

Basit Öğe Kaydı
dc.contributor.authorArgun Kurum, Gamze
dc.contributor.authorKaya Dağıstanlı, Fatma
dc.contributor.authorÖztürk, Melek
dc.date.accessioned2024-07-12T21:00:22Z
dc.date.available2024-07-12T21:00:22Z
dc.date.issued2019en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractType 2 diabetes mellitus is a complex and progressive disease. New treatment strategies including enhances and prolongs the action of the endogenous incretin hormones. Inhibition of the enzyme dipeptidyl peptidase-4 (DPP-4) slows degradation of endogenous glucagon-like peptide-1 (GLP-1).en_US
dc.identifier.citationArgun Kurum, G., Kaya Dağıstanlı, F. ve Öztürk, M. (2014). Vildalgiptin as a dipeptidyl peptidase-4 inhibitor treatment in STZ-diabetic newborn rats. Frontiers in Medical Sciences: Diabetes, Cancer and Their Connection / Tıpta Yenilikler: Diyabet, Kanser ve İlişkileri, Maltepe Üniversitesi. s. 85.en_US
dc.identifier.endpage86en_US
dc.identifier.startpage85en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3359
dc.language.isoenen_US
dc.publisherMaltepe Üniversitesien_US
dc.relation.ispartofFrontiers in Medical Sciences: Diabetes, Cancer and Their Connection / Tıpta Yenilikler: Diyabet, Kanser ve İlişkilerien_US
dc.relation.publicationcategoryUluslararası Konferans Öğesi - Başka Kurum Yazarıen_US
dc.rightsCC0 1.0 Universal*
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.snmzKY07435
dc.subjectExprimental diabetesen_US
dc.subjectSTZ-diabetic newborn ratsen_US
dc.subjectDPP4 inhibitoren_US
dc.subjectVildagliptinen_US
dc.titleVildalgiptin as a dipeptidyl peptidase-4 inhibitor treatment in STZ-diabetic newborn ratsen_US
dc.typeConference Object
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu